| INTRODUCTION
Pulmonary arterial hypertension (PAH) results from pulmonary vascular disease and may eventually lead to right heart failure and death. Available data on targeted PAH therapies suggest that they are well tolerated and effective in PAH patients. 1 Vasodilator therapy has greatly improved PAH prognosis; in particular, parenteral prostacyclin improves the outcome, not only by inducing pulmonary vasodilation but probably also by modulating vascular remodeling process. 2, 3 Intravenous prostacyclin is currently recommended for patients of all ages with WHO functional class IV disease, and as add-on therapy for patients remaining in class III despite correctly dosed treatment with endothelin-receptor antagonists and phosphodiesterase-5 inhibitors.
Subcutaneous (SC) treprostinil is sometimes preferred to intravenous prostacyclin in children, especially to avoid the long-term outcome associated with chronic intravenous therapy. 4 Circulating Microvesicles (MVs) are extracellular vesicles with a diameter from 100 to 1000 nm, released by shedding from the surface of hematopoietic and endothelial cells. [5] [6] [7] These MVs have the ability to interact with thrombotic process because of their procoagulant and also fibrinolytic properties. 6 Moreover, besides their role in thrombosis, microvesicles can be considerate as bioactive effectors that carry other molecules derived from the parental cells, including proteins, DNA, RNA, and microRNAs. 8 Microvesicles have been investigated in animal models of PAH 9 and proposed as direct effectors of endothelial dysfunction. In human adult pulmonary hypertension, microvesicles are a prognostic and severity marker. 10 Moreover, microvesicles have been demonstrated to be involved in pathogenesis of PAH. Indeed, highest levels of procoagulant microvesicles have been found in advanced stages of the disease, leading to the hypothesis that MVs could participate to thrombotic complications of PAH and also to the pathogenesis of plexiform lesions and vascular remodeling. 10 In- 
| Quantification of circulating MV subpopulations
Collected blood was centrifuged twice at 1500 g for 15 min and platelet-poor-plasma was stored at −80°C, as previously described in ref. 13 MVs were enumerated by flow cytometry on a Gallios flow cytometer (Beckman Coulter, Villepinte, France) as previously described in refs. 14, 15 First, MVs were selected in an FSC/SSC gate calibrated using 0.1, 0.3, 0.5, and 0.9 μm FSC calibration beads (Megamix-Plus, Biocytex, France), following the manufacturer's recommendations for the cytometer settings, as previously described in ref. 16 A 0.1-1 nm selected events were then analyzed, | 67 
| Fibrin polymerization test by turbidimetry
PMV phospholipid-related procoagulant properties were quantified using a fibrin generation test. Fibrin polymerization was analyzed using turbidimetry. Clot formation by MVs was triggered by adding 0.5 pm TF and 10 mm CaCl 2. Turbidity was recorded every 10 s at 405 nm and 37°C. An increase in turbidity reflects the dynamic process of fibrin network formation, shown in graphic form as a fibrinogram as previously described in ref. 17 Data were analyzed through the first derivative of the experimental curve, using
GraphPad Prism software (La Jolla, CA). In this analysis, peak height represents the maximum velocity of protofibril assembly, time-topeak being given by its abscissa. Turbidimetry assays were performed in duplicate.
| Spontaneous microvesicles generation test
For PMVs generation, after a gentle homogenization, whole blood was divided in two parts, the first one being added with 1.6 ng/mL treprostinil; the second half served as control. After 24-h incubation, PPP was obtained as described above and PMVs quantified as previously described. PMVs quantification has been analyzed after normalization to platelet count of each subject.
| Statistics
Data are shown as means ± SD. Intergroup comparisons were based on the Mann and Whitney non-parametric test or one-way ANOVA tests when three groups were compared. Correlations were based on the spearman correlation nonparametric test. For fibrin generation test, a binomial logistic regression was run to assess the impact of the different treatments on procoagulant properties, the two outcome being procoagulant activity present or not. All statistical tests were performed using the Stat View software package (SAS, Cary, NC). Differences with P < 0.05 were considered statistically significant. 
| Treprostinil decreases MV procoagulant activity in pediatric PAH
Further, PMV phospholipid-related procoagulant properties were quantified using a fibrin generation test. 18 All untreated patients had a significant procoagulant activity while about two thirds of 
| DISCUSSION
Considerable debate surrounds microvesicles involvement in PAH. In this study, we compared pediatric PAH patients and control subjects for endothelial, platelet, and leukocytes levels according to PAH treatment. As previously described in adults PAH, all MV subpopulations were found higher in non-treated patients. Interestingly, the present study evidenced a lower PMV count in treprostinil-treated patients compared with untreated or oral-treated PAH patients, while endothelial and leukocyte MV levels were similar. temperature, all tubes were centrifuged twice during 15 min at 1500 g to obtain platelet poor plasma (PPP). PPP was stored at −80°C. PPP samples were then defrosted on ice and centrifuged once 2 min at 13 000 g to remove debris, prior to PMV quantification. After normalization to platelet count of each subject, we observed a significant decrease of PMV generation when blood was pretreated with treprostinil. Data are means ± SD being approximately 100 times more prothrombotic than activated platelets. 26 PMV are increased in the context of adult PAH 11, 27 and could also participate to the thrombotic complications of PAH.
However, more than procoagulant vectors, MV also exert other biological activities 8 and can thereby participate in the disease development through induction of endothelial dysfunction, inflammation, cell proliferation, or contraction which are important in PAH pathophysiology.
Vasodilator therapy has greatly improved PAH prognosis.
Continuous intravenous (IV) epoprostenol, synthetic prostacyclin, was the first treatment approved for adult and children PAH and has been shown to improve survival, functional class, and quality of class.
28
In children with refractory PAH, subcutaneous (SC) treprostinil, 4 a prostacyclin analog that is chemically stable, is preferred to epoprostenol, in particular to avoid the long term risk associated with chronic IV therapy. We previously reported that treprostinil, more than just a vasodilator, modifies vascular homeostasis by modulating circulating endothelial cell count, endothelial progenitors, and VEGF plasma levels in pediatric PAH. 2, 3, 29 Our results presented here suggest that treprostinil could also exert its beneficial effect through inhibition of platelet activation, resulting in a decreased PMV generation and procoagulant activity. Whereas antiplatelet activity of prostacyclin analogs is well known, antiplatelet activity of treprostinil had never been explored so far. Our study is the first one to our knowledge to link prostacyclin analogs and PMV.
Epoprostenol has been previously described to have inhibitory effect on platelet functions in particular platelet aggregation, but also to induce a decrease in PMV and platelet leukocyte conjugate formation. 30 Treprostinil is a stable prostacyclin (PGI2) analogue. Another Our study has several limitations. First limitation is our control group. We used young healthy adults as controls and we are aware that it is not a proper matched control group. However, no data currently exist in the literature on microvesicle quantification along age. However, we think that the absence of a control group is not an issue to interpret present data. Indeed, since we always compared microvesicle level and phospholipids procoagulant activity of nontreated PAH kids to treated kids of same median age. Second, our results need also to be confirmed on a larger cohort of adult and pediatric PAH treated with different prostacyclin analogues. However, our in vitro data are in line with a direct effect on platelets.
| CONCLUSION
The present study extends the knowledge on the potential antithrombotic mechanisms of treprostinil and, in particular, its ability to prevent platelet microvesicles generation. This suggests an additional mechanism of action of this drug in reducing thrombosis but potential platelet related inflammatory cell contribution to pulmonary hypertension.
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